1                                                     F                                                                   ...
1                                                                                                                         ...
1234                 1.                                                              F5                                 F ...
Kawasaki et al (2008)                                     RCT                           Knee                             1...
1                Reginster       (2001)                                    Pavelka                                        ...
1                      F                                      F                                                           ...
1    Wilkens P, Scheel I, Grundnes O, Hellum C, Storheim K. (2010). Effect of glucosamine on pain-related disability in pa...
1    The National Centre for Pharmacoeconomics (NCPE) in Ireland. (2009). Economic evaluation of glucosamine sulfate2     ...
1    Worcestershire APC. (2008). Recommendations for Prescription of Glucosamine for Osteoarthritis. [online]. Worcestersh...
Upcoming SlideShare
Loading in …5



Published on

Published in: Technology, Business
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide


  1. 1. 1 F F F Glucosamine2 F F F3 F4 08/09/1056 (Glucosamine) F 95 F7 F F F F F8 F F F F F F9 F crystalline form F F F F10 F F (All forms of degenerative11 osteoarticular disease) F12 F (Primary) F F13 (Secondary) F14 F Cervical arthrosis, Coxofemoral arthrosis, Gonarthrosis, Dosal15 Arthrosis, Lumbosacral arthrosis, Scapulohumeral arthrosis, Periarthritis,16 Lumbago, Fractures, Osteoarticular dystrophies, Chronic and subacute arthritis17 F F F F18 F F( F F / ) 26 F 1019 2552 F F F F 380 F F20 3 F F F F ( ., 2553) F F F F21 F FF F F F22 F F F 1
  2. 2. 1 F2 F F F F F3 F F4 F F F56 1. F F F7 F8 2. F F F F9 3. F F F10 F F11 F F F meta-analysis randomized12 controlled trials (RCT) F F . 2005-2010 F F 3113 1 2553 F Pubmed Cochrane F keywords Glucosamine and14 osteoarthritis inclusion criteria F F F 1215 F F F F keywords F Glucosamine and cost-effectiveness16 F Pubmed Cochrane F F F17 F Google keywords Glucosamine and osteoarthritis F F18 F F F F personal file F F 219 F20 1 F F F Keywords F PubMed Cochrane F F Glucosamine and osteoarthritis 32 12 9 Glucosamine and cost-effectiveness 2 2 2 F 2
  3. 3. 1234 1. F5 F F FF ( 2) F6 F F F (statistical non-significance, NS) F F7 Western Ontario and McMaster Universities (WOMAC) pain WOMAC function8 F F (Sawitzke et al.,2010, Lee et al.,2010, Kawasaki et al., 2008, Messier et al., 2007)9 F (Rozendaal et al.,2009) F F Roland Morris Disability10 Questionnaire (RMDQ) F EuroQol-5 (EQ-5D) F (Wilkens11 et al.,2010)12 2 F F F F F F Lee et al.(2010) Meta- Knee 1,502† GS vs JSW NS (1 year) analysis placebo Small/moderate (3 years) Sawitzke et al.(2010) RCT Knee 662 Glucosamine WOMAC pain NS vs placebo WOMAC function Wilkens et al (2010) RCT Lumbar 250 Glucosamine RMDQ NS vs placebo EQ-5D Rozendaal et al (2009)* RCT Hip 222 GS vs WOMAC pain NS Rozendaal et al (2008) placebo WOMAC function JSW Sawitzke et al.(2008) RCT Knee 572 Glucosamine JSW NS vs placebo F 3
  4. 4. Kawasaki et al (2008) RCT Knee 142 GH vs JSW NS placebo Messier et al.(2007) RCT Knee 89 GH vs WOMAC function NS placebo WOMAC pain1 GH = Glucosamine Hydrochloride, GS = Glucosamine Sulfate2 NS = Statistically non-significant difference3 * Subgroup analysis4 † Glucosamine F (Chondroitin) F5 F F F F F F F F (joint6 space width, JSW) F F F F F F F F7 F F (Lee et al.,2010) F (Lee et al.,2010,Rozendaal et al,2009,8 2008, Sawitzke et al.,2008, Kawasaki et al.,2008)9 F F F F10 (Bruyere et al., 2008) F F F F 200111 2002 (N=275 N=340) F intent to treat1 F F F12 F F 5 F F 1 F13 F F F F214 meta-analysis Towheed et al. (2009) RCT15 25 F 4,963 F 1980 - 2008 F F F16 F F F F F17 F18 2. F F F19 F F F F2 (Black,200920 Scholtissen et al, 2010) (Black et al, 2009) Markov FF 1 F F F 1) F F F F F F F F F F F F 2) F F FF F F F F 2 F F F F F 4
  5. 5. 1 Reginster (2001) Pavelka (2002) F2 Chaiyakunapruk (2010) F F F F F3 F F F ( F4 F NSAID COX-II) F F (incremental cost-effectiveness ratio, ICER) F5 F 774,125 F (quality-adjusted life year, QALY)6 F Viatril-S® F F 2,612,605 F F F7 F F F F F ( F 1 GDP per capita 100,000 F ) F8 (Scholtissen et al, 2010) F F RCT Reginster (2001)9 Pavelka (2002) F F F F (utility) F10 F F11 3. F12 F F13 F F F F14 F F F F FF15 F16 F F F17 National Institute of Clinical Excellence (NICE3) guideline (2008) F F F18 F F F (National Health Service, NHS)19 F F F F F F F FF F20 F F F F (NCPE, 2009, SMC, 2008, Mid Essex,2008,21 Oxfordshire, 2008, Berkshire PC,2008, OxPF,2008, Suffolk PCT, 2008, North Staffordshire APC, 2008,22 South Staffordshire APC, 2008, Worcestershire APC, 2008) 3 F F FF F F F 5
  6. 6. 1 F F (The Dental and2 Pharmaceutical Benefits Agency, TLV) F F F3 F F F F F (TLV, 2010)4 F F5 F FF F6 F F F F F7 F F8 F F F F F F F F F F F910 F F F11 F F F F F12 F F F F13 F14 ( .) (2553). F F15 F 34 F F .16 Sawitzke A, Shi H, Finco M, Dunlop D, Harris C, Singer N, et al. (2010). Clinical efficacy and safety of glucosamine,17 chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results18 from GAIT. Annals of the Rheumatic Diseases. Aug;69(8):1459-64.19 Sawitzke A, Shi H, Finco M, Dunlop D, Bingham III C, Harris C, et al. (2008). The effect of glucosamine and/or chondroitin20 sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention21 trial. Arthritis & Rheumatism. 58(10):3183-91.22 Kawasaki T, Kurosawa H, Ikeda H, Kim S, Osawa A, Takazawa Y, et al. (2008). Additive effects of glucosamine or23 risedronate for the treatment of osteoarthritis of the knee combined with home exercise: a prospective randomized24 18-month trial. Journal of bone and mineral metabolism. 26(3):279-87. F 6
  7. 7. 1 Wilkens P, Scheel I, Grundnes O, Hellum C, Storheim K. (2010). Effect of glucosamine on pain-related disability in patients2 with chronic low back pain and degenerative lumbar osteoarthritis: a randomized controlled trial. JAMA.3 304(1):45.4 Rozendaal R, Uitterlinden E, van Osch G, Garling E, Willemsen S, Ginai A, et al. (2009). Effect of glucosamine sulphate on5 joint space narrowing, pain and function in patients with hip osteoarthritis; subgroup analyses of a randomized6 controlled trial. Osteoarthritis and cartilage. 17(4):427-32.7 Lee Y, Woo J, Choi S, Ji J. (2009). Effect of glucosamine or chondroitin sulphate on osteoarthritis progression: a meta-8 analysis. Rheumatol Int. Jan(30(3)):357-63.9 Scholtissen S, Bruyère O, Neuprez A, Severens JL, Herrero-Beaumont G, Rovati L, Hiligsmann M, Reginster JY.10 (2010).Glucosamine sulphate in the treatment of knee osteoarthritis: cost-effectiveness comparison with11 paracetamol. Int J Clin Pract. May;64(6):756-62.12 Chaiyakunapruk N, Saokaew S, Pansang S. (2010). Cost-Effectiveness Analysis of Glucosamine Sulphate for The Treatment13 of Osteoarthritis in Thailand. 4th Asia Pacific International Society of Pharmacoeconomics and Outcomes14 Research Sept 5th-7th, 2010 at Phuket, Thailand. (Oral Presentation).15 Black C, Clar C, Henderson R, MacEachern C, McNamee P, Quayyum Z, Royle P, Thomas S. (2009). The clinical16 effectiveness of glucosamine and chondroitin supplements in slowing or arresting progression of osteoarthritis of17 the knee: a systematic review and economic evaluation. Health Technology Assessment. Nov;13(52):1-148.18 Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC. (2002). Glucosamine sulfate use and delay of19 progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med.20 162: 2113-23.21 Reginster JY, Deroisy R, Rovati LC, et al. (2001.) Long-term effects of glucosamine sulphate on osteoarthritis progression: a22 randomised, placebo-controlled clinical trial. Lancet ;357:251-6.23 National Institute for Health and Clinical Excellence. (2008). Osteoarthritis: the care and management of osteoarthritis in24 adult. London. Clinical guideline;no.59.25 Towheed, T.E,.Maxwell, L.,Anastassisdes, T.P., Shea, B., Houpt, T., Robinson, V., Hochberg, M.C.&Wells,G.26 (2009).Glucosamine therapy for treating osteoarthritis (Review). Cochrane Library. F 7
  8. 8. 1 The National Centre for Pharmacoeconomics (NCPE) in Ireland. (2009). Economic evaluation of glucosamine sulfate2 (DONA) for the treatment of osteoarthritis in the Irish healthcare setting. [online]. Dublin:NCPE. Available from :3 http://www.ncpe.ie/u_docs//doc_171.pdf [Accessed 2 September 2010]4 Scottish Medicines Consortium (SMC). (2008). Advice on glucosamine (as hydrochloride), 625mg tablets (Alateris®).5 [online]. No. 471/08. Lothian:NHS Scotland. Available from :6 http://www.scottishmedicines.org.uk/files/glucosamine%20%20Alateris%20FINAL%20May%202008%20for%207 website.pdf. [Accessed 2 September 2010]8 Mid Essex Area Prescribing Committee. (2008). Glucosamine for osteoarthritis. [online].Mid Essex Locality. Available9 from : http://www.midessex.nhs.uk/Documents10 /Key%20Documents/Policies%20and%20Procedures/Medicines%20Management%20Policies%20and%20Procedu11 res/Glucosamine%20Policy%20Statement.pdf. [Accessed 2 September 2010]12 Oxfordshire Priorities Forum. (2008). Glucosamine (sulphate and hydrochloride salt) for adult osteoarthritis. [online].13 Oxfordshire PCT. Available from : http://www.oxford14 Berkshire Priorities Committee. (2008). Minutes of meeting on Glucosamine for OA knee. [online]. Berkshire. Available15 from : http://www.berkshire.nhs.uk/priorities/ _policies/Minutes-3-September-2008.pdf. [Accessed 2 September16 2010]17 Suffolk PCT Drug & Therapeutics Committee. (2008). New Medicine Report. Glucosamine Hydrochloride (Alateris,18 William Ransom & Son). [online]. Suffolk. Available from :19 http://www.suffolkextranet.nhs.uk/LinkClick.aspx?fileticket=lgx4Q4L2EJs%3D&tabid=966&mid=1797.20 [Accessed 2 September 2010]21 North Staffordshire Area Prescribing Committee. (2008). New Medicine Review and Verdict. Glucosamine hydrochloride22 (AlaterisTM). [online]. North Staffordshire. Available from :23 http://www.medicinesmanagementstoke.nhs.uk/documents/Glucosamine_Ref_JAN08.pdf. [Accessed 224 September2010]25 South Staffordshire APC.(2008).Glucosamine.[online]. South Staffordshire. Available26 from:http://www.southstaffordshirepct.[Accessed 2 September 2010] F 8
  9. 9. 1 Worcestershire APC. (2008). Recommendations for Prescription of Glucosamine for Osteoarthritis. [online]. Worcestershire2 APC. Avialable from :http://www.worcspct.nhs.uk/publications/policies-and-procedures/medicine-management--3 pharmacy /area-prescribing-committee.aspx#musculo. [Accessed 1 September 2010]4 The Midlands Therapeutics Review and Advisory Committee (MTRAC).(2008). Glucosamine in osteoarthritis. [online].5 Available from : http://www.nelm.nhs.uk/ en/NeLM-Area/Evidence/Drug-Specific-Reviews/MTRAC. [Accessed 16 September 2010]7 The Swedish Dental and Pharmaceutical Benefits agency. Glucosamine excluded from the reimbursement system. Interim8 decision from the review of painkillers and anti-inflammatory medicines. THE DECISIONS COME INTO FORCE9 on 2010-05-15. [online]. Available from : http://tlv.se/Upload/Genomgangen/100517-tlv-interim-decision-10 glucosamine.pdf. [Accessed 2 September 2010] F 9